Minerva Neurosciences reported $27.44M in Current Assets for its fourth fiscal quarter of 2020.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Current Assets Change
Acadia Pharmaceuticals ACAD:US $ 717.62M 12.6M
ALKERMES ALKS:US 1.11B 86.03M
Arena Pharmaceuticals ARNA:US $ 1139.31M 62.94M
AstraZeneca AZN:LN 19.54B 1.38B
Biocryst Pharmaceuticals BCRX:US $ 323.8M 161.36M
Bristol Myers Squibb BMY:US $ 30192M 4085M
Dynavax Technologies DVAX:US $ 290.02M 0.01M
Eli Lilly And LLY:US $ 17462.1M 1222.2M
Esperion Therapeutics ESPR:US $ 345.9M 103.09M
GlaxoSmithKline GSK:LN 20.25B 366M
Halozyme Therapeutics HALO:US $ 554.76M 55.87M
IONIS PHARMACEUT IONS:US $ 2130.71M 406.27M
Johnson & Johnson JNJ:US $ 51237M 6341M
Merk MRK:US $ 27764M 1187M
Neurocrine Biosciences NBIX:US $ 1016.2M 140.7M
Novartis NOVN:VX 29.67B 700M
Pfizer PFE:US $ 35067M 12672M
Takeda 4502:JP Y 2616598M 31462M
Vanda Pharmaceuticals VNDA:US $ 409.14M 19.61M